-
1.发明申请公开(公告)号：US20160339065A1
公开(公告)日：2016-11-24
申请号：US15161654
申请日：2016-05-23
申请人： Arizona Board of Regents on behalf of Arizona State University , Regents of the University of Minnesota , Crestovo LLC
发明人： James ADAMS , Rosa KRAJMALIK-BROWN , Dae-Wook KANG , Michael J. SADOWSKY , Alexander KHORUTS , Thomas J. BORODY
IPC分类号： A61K35/741 , A61K38/08 , A61K45/06
CPC分类号： A61K38/08 , A61K35/74 , A61K38/14 , A61K45/06 , A61K2035/128 , A61K2300/00
摘要： The present disclosure relates to compositions and methods for treating autism spectrum disorder (ASD) by restoring an ASD patient's gut microbiota. These methods can be used with ASD patient with or without ongoing gastrointestinal symptoms. Provided here is a method for ASD treatment in a subject in need thereof comprising or consisting essentially of administering a therapeutic composition comprising a fecal microbe or a fecal microbiota preparation to the subject. Also provided here is a method comprises administering an antibiotic to a human subject; subjecting the human subject to a bowel cleanse; and administering purified fecal microbiota to the human subject. Further provided are evaluation and quantitative characterization of patient symptom improvements upon treatment described here.
摘要翻译： 本公开涉及通过恢复ASD患者的肠道微生物群来治疗自闭症谱系障碍（ASD）的组合物和方法。 这些方法可以与ASD患者一起使用，无论是否有持续的胃肠道症状。 这里提供了一种在有需要的受试者中进行ASD治疗的方法，其包括或基本上由给予受试者的包含粪便微生物或粪便微生物群制剂的治疗组合物组成。 这里还提供了一种方法，包括向人受试者施用抗生素; 使人类受试者进行肠道清洁; 并向人类受试者施用纯化的粪便微生物群。 进一步提供了这里描述的治疗后患者症状改善的评估和定量表征。
-
公开(公告)号：US20200061148A1
公开(公告)日：2020-02-27
申请号：US16548404
申请日：2019-08-22
申请人： Arizona Board of Regents on behalf of Arizona State University , Regents of the University of Minnesota , Crestovo Holdings LLC
发明人： James ADAMS , Rosa KRAJMALNIK-BROWN , Dae-Wook KANG , Michael J. SADOWSKY , Alexander KHORUTS , Thomas J. BORODY
摘要： The present disclosure relates to compositions and methods for treating autism spectrum disorder (ASD) by restoring an ASD patient's gut microbiota. These methods can be used with ASD patient with or without ongoing gastrointestinal symptoms. Provided here is a method for ASD treatment in a subject in need thereof comprising or consisting essentially of administering a therapeutic composition comprising a fecal microbe or a fecal microbiota preparation to the subject. Also provided here is a method comprises administering an antibiotic to a human subject; subjecting the human subject to a bowel cleanse; and administering purified fecal microbiota to the human subject. Further provided are evaluation and quantitative characterization of patient symptom improvements upon treatment described here.
-
公开(公告)号：US20220088089A1
公开(公告)日：2022-03-24
申请号：US17539767
申请日：2021-12-01
申请人： Arizona Board of Regents on behalf of Arizona State University , Regents of the University of Minnesota , Finch Therapeutics Holdings LLC
发明人： James ADAMS , Rosa KRAJMALNIK-BROWN , Dae-Wook KANG , Michael J. SADOWSKY , Alexander KHORUTS , Thomas J. BORODY
IPC分类号： A61K35/741 , A61K45/06 , A61K38/08 , A61K38/14 , A61K35/74
摘要： The present disclosure relates to compositions and methods for treating autism spectrum disorder (ASD) by restoring an ASD patient's gut microbiota. These methods can be used with ASD patient with or without ongoing gastrointestinal symptoms. Provided here is a method for ASD treatment in a subject in need thereof comprising or consisting essentially of administering a therapeutic composition comprising a fecal microbe or a fecal microbiota preparation to the subject. Also provided here is a method comprises administering an antibiotic to a human subject; subjecting the human subject to a bowel cleanse; and administering purified fecal microbiota to the human subject. Further provided are evaluation and quantitative characterization of patient symptom improvements upon treatment described here.
-
公开(公告)号：US20190328825A1
公开(公告)日：2019-10-31
申请号：US16510506
申请日：2019-07-12
申请人： Arizona Board of Regents on behalf of Arizona State University , Regents of the University of Minnesota , Crestovo Holdings LLC
发明人： James ADAMS , Rosa KRAJMALNIK-BROWN , Dae-Wook KANG , Michael J. SADOWSKY , Alexander KHORUTS , Thomas J. BORODY
摘要： The present disclosure relates to compositions and methods for treating autism spectrum disorder (ASD) by restoring an ASD patient's gut microbiota. These methods can be used with ASD patient with or without ongoing gastrointestinal symptoms. Provided here is a method for ASD treatment in a subject in need thereof comprising or consisting essentially of administering a therapeutic composition comprising a fecal microbe or a fecal microbiota preparation to the subject. Also provided here is a method comprises administering an antibiotic to a human subject; subjecting the human subject to a bowel cleanse; and administering purified fecal microbiota to the human subject. Further provided are evaluation and quantitative characterization of patient symptom improvements upon treatment described here.
-
公开(公告)号：US20190134144A1
公开(公告)日：2019-05-09
申请号：US16235635
申请日：2018-12-28
申请人： Arizona Board of Regents on behalf of Arizona State University , Regents of the University of Minnesota , Crestovo Holdings LLC
发明人： James ADAMS , Rosa KRAJMALNIK-BROWN , Dae-Wook KANG , Michael J. SADOWSKY , Alexander KHORUTS , Thomas J. BORODY
摘要： The present disclosure relates to compositions and methods for treating autism spectrum disorder (ASD) by restoring an ASD patient's gut microbiota. These methods can be used with ASD patient with or without ongoing gastrointestinal symptoms. Provided here is a method for ASD treatment in a subject in need thereof comprising or consisting essentially of administering a therapeutic composition comprising a fecal microbe or a fecal microbiota preparation to the subject. Also provided here is a method comprises administering an antibiotic to a human subject; subjecting the human subject to a bowel cleanse; and administering purified fecal microbiota to the human subject. Further provided are evaluation and quantitative characterization of patient symptom improvements upon treatment described here.
-
公开(公告)号：US20170319627A1
公开(公告)日：2017-11-09
申请号：US15655393
申请日：2017-07-20
IPC分类号： A61K35/37 , A61K47/26 , A61K47/08 , A61K35/742 , A61K9/00 , A61K35/24 , A61K9/16 , A61K35/74 , A61K35/741 , A61K35/00
摘要： The present invention provides compositions that include an extract of human feces, and methods for using such compositions, including methods for replacing or supplementing or modifying a subject's colon microbiota, and methods for treating a disease, pathological condition, and/or iatrogenic condition of the colon.
-
公开(公告)号：US20190247445A1
公开(公告)日：2019-08-15
申请号：US16313791
申请日：2017-07-03
摘要： The present disclosure provides compositions and methods for treating Clostridium difficile infection (CDI) including primary and recurrent CDI. In particular, the compositions and methods described herein are capable of achieving a CDI clearance rate of at least 80% through a single oral dose of a pharmaceutical composition comprising a freeze-dried fecal microbiota preparation.
-
公开(公告)号：US20180028574A1
公开(公告)日：2018-02-01
申请号：US15626898
申请日：2017-06-19
IPC分类号： A61K35/37 , A61K35/742 , A61K47/26 , A61K35/24 , A61K47/08
摘要： The present invention provides compositions that include an extract of human feces, and methods for using such compositions, including methods for replacing or supplementing or modifying a subject's colon microbiota, and methods for treating a disease, pathological condition, and/or iatrogenic condition of the colon.
-
公开(公告)号：US20240342222A1
公开(公告)日：2024-10-17
申请号：US18583572
申请日：2024-02-21
IPC分类号： A61K35/37 , A61K9/00 , A61K9/16 , A61K35/00 , A61K35/24 , A61K35/74 , A61K35/741 , A61K35/742 , A61K45/06 , A61K47/08 , A61K47/26
CPC分类号： A61K35/37 , A61K9/0053 , A61K9/16 , A61K9/1617 , A61K9/1623 , A61K35/24 , A61K35/74 , A61K35/741 , A61K35/742 , A61K45/06 , A61K47/08 , A61K47/26 , A61K2035/11 , Y02A50/30
摘要： The present invention provides compositions that include an extract of human feces, and methods for using such compositions, including methods for replacing or supplementing or modifying a subject's colon microbiota, and methods for treating a disease, pathological condition, and/or iatrogenic condition of the colon.
-
公开(公告)号：US20240050489A1
公开(公告)日：2024-02-15
申请号：US18485872
申请日：2023-10-12
CPC分类号： A61K35/74 , A01N1/02 , A61K9/0053 , A61P31/04 , A61K9/19 , A61K31/43 , A61K9/1682 , A61K9/2095 , A61K9/1623
摘要： The present disclosure provides compositions and methods for treating Clostridium difficile infection (CDI) including primary and recurrent CDI. In particular, the compositions and methods described herein are capable of achieving a CDI clearance rate of at least 80% through a single oral dose of a pharmaceutical composition comprising a freeze-dried fecal microbiota preparation.
-
-
-
-
-
-
-
-
-
搜索结果
18 条记录 (耗时 0.037 秒)
